リスプロ
- 関
- Humalog、insulin lispro、lispro insulin
WordNet
- speak with a lisp
- a speech defect that involves pronouncing `s like voiceless `th and `z like voiced `th
PrepTutorEJDIC
- 舌たらずに発音する(特に[s][z]を発音する) / …‘を'舌たらずに発音する / 舌足らずの発音
Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2014/01/24 05:10:09」(JST)
[Wiki en表示]
|
|
This article needs attention from an expert on the subject. Please add a reason or a talk parameter to this template to explain the issue with the article. Consider associating this request with a WikiProject. (March 2010) |
|
|
This article relies on references to primary sources. Please add references to secondary or tertiary sources. (March 2010) |
Insulin lispro
|
| Clinical data |
| AHFS/Drugs.com |
monograph |
| MedlinePlus |
a697021 |
| Pregnancy cat. |
C (US) |
| Legal status |
POM (UK) ℞-only (US) |
| Routes |
Subcutaneous |
| Identifiers |
| CAS number |
133107-64-9 Y |
| ATC code |
A10AB04 |
| PubChem |
CID 16132438 |
| DrugBank |
DB00046 |
| UNII |
GFX7QIS1II N |
| KEGG |
D04477 Y |
| Chemical data |
| Formula |
C257H389N65O77S6 |
| Mol. mass |
5813.63 g/mol |
| N (what is this?) (verify) |
Insulin lispro (marketed by Eli Lilly and Company as "Humalog") is a fast acting insulin analogue. It was first approved for use in the United States in 1996, making it the first insulin analogue to enter the market.[1]
Engineered through recombinant DNA technology, the penultimate lysine and proline residues on the C-terminal end of the B-chain are reversed. This modification does not alter receptor binding, but blocks the formation of insulin dimers and hexamers. This allowed larger amounts of active monomeric insulin to be immediately available for postprandial injections.[2]
Insulin lispro has one primary advantage over regular insulin for postprandial glucose control. It has a shortened delay of onset, allowing slightly more flexibility than regular insulin, which requires a longer waiting period before starting a meal after injection. Both preparations should be coupled with a longer acting insulin for good glycemic control.
References[edit]
- ^ "Drugs@FDA:FDA Approved Products: Humalog". U.S. Food and Drug Administration. Retrieved 16 November 2012.
- ^ "Insulin Lispro: A Fast-Acting Insulin Analog". Retrieved 2007-06-08.
External links[edit]
- FDA Warning Letter to Lilly re: instability of Humalog Crystals-February 22, 2010
|
Oral anti-diabetic drugs and Insulin analogs (A10)
|
|
| Insulin |
|
Sensitizers
|
|
Biguanides
|
- Metformin#
- Buformin‡
- Phenformin‡
|
|
|
TZDs/"glitazones" (PPAR)
|
- Pioglitazone
- Rivoglitazone†
- Rosiglitazone
- Troglitazone‡
|
|
|
Dual PPAR agonists
|
- Aleglitazar†
- Muraglitazar§
- Saroglitazar
- Tesaglitazar§
|
|
|
|
Secretagogues
|
|
K+ ATP
|
|
Sulfonylureas
|
- 1st generation: Acetohexamide
- Carbutamide
- Chlorpropamide
- Metahexamide
- Tolbutamide
- Tolazamide
2nd generation: Glibenclamide (Glyburide)#
- Glibornuride
- Glipizide
- Gliquidone
- Glisoxepide
- Glyclopyramide
- Glimepiride
- Gliclazide
|
|
|
Meglitinides/"glinides"
|
- Nateglinide
- Repaglinide
- Mitiglinide
|
|
|
|
GLP-1 agonists
|
- Exenatide
- Liraglutide
- Taspoglutide†
- Albiglutide†
- Lixisenatide
|
|
|
DPP-4 inhibitors
|
- Alogliptin
- Anagliptin
- Gemigliptin
- Linagliptin
- Saxagliptin
- Sitagliptin
- Teneligliptin
- Vildagliptin
|
|
|
GPR40 Free fatty acid receptor 1
|
|
|
|
|
Analogs/other insulins
|
- fast-acting (Insulin lispro
- Insulin aspart
- Insulin glulisine)
- short-acting (Regular insulin)
- long-acting (Insulin glargine
- Insulin detemir
- NPH insulin)
- ultra-long-acting (Insulin degludec†)
- inhalable Exubera‡
|
|
|
| Other |
|
Alpha-glucosidase inhibitors
|
- Acarbose
- Miglitol
- Voglibose
|
|
|
Amylin analog
|
|
|
|
SGLT2 inhibitors
|
- Canagliflozin
- Dapagliflozin
- Empagliflozin†
- Remogliflozin§
- Sergliflozin§
- Tofogliflozin†
|
|
|
Other
|
- Bromocriptine
- Benfluorex‡
- Tolrestat‡
|
|
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
|
|
|
|
|
noco (d)/cong/tumr, sysi/epon
|
proc, drug (A10/H1/H2/H3/H5)
|
|
|
|
Template:Endocrine-drug-stub
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
English Journal
- Safety of insulin analogues as compared with human insulin in pregnancy.
- Hod M1, Toledano Y1, Hadar E1, Tikva P2.
- Expert opinion on drug safety.Expert Opin Drug Saf.2016 May 4. [Epub ahead of print]
- INTRODUCTION: Diabetes during pregnancy may lead to maternal, fetal and neonatal complications. In order to limit unwarranted outcomes, strict glycemic control is essential. In the past, human insulin was the only insulin formulation administered in pregnancy. However, insulin analogues have also be
- PMID 27145344
- Insulin analogues in pregnancy and specific congenital anomalies: a literature review.
- de Jong J1, Garne E2, Wender-Ozegowska E3, Morgan M4, de Jong-van den Berg LT1, Wang H1.
- Diabetes/metabolism research and reviews.Diabetes Metab Res Rev.2016 May;32(4):366-75. doi: 10.1002/dmrr.2730. Epub 2015 Nov 6.
- Insulin analogues are commonly used in pregnant women with diabetes. It is not known if the use of insulin analogues in pregnancy is associated with any higher risk of congenital anomalies in the offspring compared with use of human insulin. We performed a literature search for studies of pregnant w
- PMID 26431249
- Hypoglycemic treatment of diabetic patients in the Emergency Department.
- Caballero Requejo C1, Urbieta Sanz E1, Trujillano Ruiz A1, García-Molina Sáez C1, Onteniente Candela M1, Piñera Salmerón P2.
- Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria.Farm Hosp.2016 May 1;40(n03):172-186.
- in
English, SpanishObjetivo: Analizar la adecuacion del tratamiento hipoglucemiante prescrito en el Servicio de Urgencias a las recomendaciones de consenso disponibles, asi como evaluar su repercusion clinica. Método: Estudio observacional descriptivo. Se incluyeron pacientes que se encontraban
Japanese Journal
- Comparison of short-term effectiveness of introducing insulin treatment between intensive and thrice-daily lispro 50/50 therapy
- Masuda Kiyomi,Aoki Kazutaka,Togashi Yu [他]
- 横浜医学 62(4), 487-493, 2011-10
- NAID 40019164222
- 超速効型インスリンアナログの大量注射により血糖降下作用が遷延した2型糖尿病の1例
- 須田 健一,橋本 俊彦,江藤 知明 [他],岡田 朗
- 糖尿病 = Journal of the Japan Diabetes Society 51(4), 329-333, 2008-04-30
- NAID 10021275096
- インスリンリスプロ混合製剤-50注1日3回投与法の検討
- 小川 浩平,赤尾 雅也,清水 学 [他],林 良成,岡山 直司,神谷 吉宣
- 糖尿病 = Journal of the Japan Diabetes Society 51(3), 227-232, 2008-03-30
- NAID 10021274937
Related Links
- Insulin lispro must be injected shortly before or after a meal. If you remember your dose before or shortly after your meal, inject the missed dose right away. If some time has passed since your meal, follow the ...
- Consumer information about the medication INSULIN LISPRO - INJECTION (Humalog), includes side effects, drug interactions, recommended dosages, and storage information. Read more about the prescription drug INSULIN ...
★リンクテーブル★
[★]
- 英
- lispro、insulin lispro、lispro insulin
- 関
- リスプロインスリン、インスリンリスプロ、ヒューマログ